Table 3.
Cumulative risk of ALL relapse according to CASP8AP2 expression in relation to that of other selected clinical and biologic variables
95% Cl of hazard ratio
|
||||
---|---|---|---|---|
Variable | Hazard ratio | Lower | Upper | P |
CASP8AP2 expression | ||||
Low vs high* | 7.98‡ | 1.45 | 43.83 | .017 |
Log-transformed signal† | 6.32‡ | 1.83 | 21.79 | .004 |
Age, y | ||||
Younger than 1 vs 1 to 10 | 5.63 | 0.71 | 44.61 | .100 |
Older than 10 vs 1 to 10 | 10.33‡ | 3.00 | 35.61 | <.001 |
WBC, × 109/L | ||||
More than 10 to 49 vs 10 or less | 0.86 | 0.22 | 3.38 | .830 |
50 to 99 vs 10 or less | 2.72 | 0.50 | 14.72 | .240 |
100 or more vs 10 or less | 4.15 | 0.95 | 18.22 | .059 |
Genotype (B-lineage only) | ||||
BCR-ABL vs other | 6.45‡ | 1.69 | 24.65 | .001 |
E2A-PBX vs other | 0.96 | 0.26 | 3.47 | .940 |
MLL-AF4 vs other | 1.70 | 0.54 | 5.38 | .370 |
TEL-AML1 vs other | 5.18 | 0.96 | 27.92 | .056 |
Hyperdiploidy vs other | 0.37 | 0.03 | 4.62 | .440 |
Lineage | ||||
T vs B | 6.12‡ | 1.58 | 23.78 | .009 |
Analyzed using Fine and Gray's estimator.35
Comparisons of relapse hazards for 33 patients with the lowest levels of CASP8AP2 expression versus the 33 patients with the highest levels.
Increase of risk per unit decrease in log CASP8AP2 expression.